Drugs and Devices

FDA approves new drug for Duchenne muscular dystrophy

On Feb. 9, the U.S. Food and Drug Administration (FDA) approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (the most common type of muscular dystrophy). Read more 


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares